



ASX, Nasdaq and Media Release

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Melbourne, Australia; September 7, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will present at H.C. Wainwright's 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.

Mr. Morris will present on Wednesday, September 13th at 12:00PM – 12:30PM EST (2:00 AM September 14th AEDT), which can be accessed live by registering at: <https://journey.ct.events/view/f538e04f-dd74-4f59-aa96-7164bf6856e6>. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at <https://www.opthea.com/presentations/>.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

Opt

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

U.S.A. & International:

Megan Baldwin CEO
Opthea Limited
Tel: +61 (0) 447 788 674

Australia:

Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333

Media:

Hershel Berry
Blueprint Life Science Group
Tel: +1 415 505 3749
hberry@bplifescience.com

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com